Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of LY3462817 in moderately to severely active rheumatoid arthritis
2020-002673-10Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in rheumatoid arthritis (RA) comparing LY3462817 with Placebo (2 arms). Primary endpoint: Change from baseline in DAS28-hsCRP. Started Dec 2020; status: completed.
02
Drugs
peresolimab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2020-002673-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002673-10.